Locations:

Better, Faster, Stronger: Intensity-Modulated, Accelerated Partial Breast Radiation Therapy

Full treatment in five fractions

Dr.Murphy&EDGE_650x450

When Chirag Shah, MD, became a radiation oncologist in 2007, almost all breast cancer patients had one option: five to six weeks of daily, whole-breast/chest-wall radiation, regardless of surgical type (mastectomy or lumpectomy). A mere decade later, thanks to advances in the field in part refined at Cleveland Clinic Cancer Center, patients can choose among several options for radiotherapy, many of which are safer and shorter without compromising efficacy. Dr. Shah is directing Cleveland Clinic Cancer Center’s adoption of new techniques to significantly reduce the duration of radiation therapy treatments for appropriately selected patients, from three to four weeks to just five treatments.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Intensity-modulated, accelerated partial breast radiation therapy

Accelerated partial-breast irradiation (APBI) allows appropriately selected patients with early-stage breast cancer to complete adjuvant radiation in two weeks or less following breast-conserving surgery. To date, multiple randomized trials have demonstrated no difference in rates of recurrence or survival with APBI delivered using brachytherapy or external beam radiation techniques.

For patients with ductal carcinoma in situ (DCIS) ­and early-stage invasive breast cancer, APBI has been shown to be an alternative to standard whole-breast irradiation, allowing for a reduction in the duration of radiation therapy. The technique, by reducing the amount of normal, healthy breast tissue treated with radiation, may also reduce side effects of treatment and improve cosmetic outcomes. It is also considered a cardiac and pulmonary dose-sparing technique.

One method of delivering APBI is intensity-modulated radiation therapy (IMRT), a highly precise form of radiotherapy. Cleveland Clinic Cancer Center employs a team of highly trained specialists that utilize the Edge® (Varian Medical Systems Inc.) radiosurgical suite. The Edge is a state-of-the-art linear accelerator coupled with real-time motion management to ensure fast, precise delivery of treatment. The six-degree freedom couch, which accounts for motion in multiple directions, allows for accurate patient positioning while a CT scan attached to the machine allows accurate targeting of the area at risk.

”Combining active breathing control (ABC) with IMRT reduces cardiac dosing even further,” says Dr. Shah, Director of Clinical Research and Breast Radiation in the Department of Radiation Oncology. “We can usually line this up with an accuracy of within a few millimeters.”

Advertisement

IMRT is commonly used to treat prostate, head and neck and central nervous system cancers. Dr. Shah’s team is refining its use in breast cancer to deliver partial breast irradiation. IMRT can deliver higher doses with fewer side effects and reduced treatment toxicity, but it does require more planning than other traditional methods. “Still, we’ve submitted a study showing that our five-fraction treatment reduces costs for patients and health systems. Although it uses more advanced technology, it saves money because of fewer treatments, less time in treatment, less missed work and reduced overall expenses.”

With a variety of innovations and radiation technique trials available to patients, Dr. Shah is optimistic about the ability of breast radiation oncology to increase its impact on patient survival and quality of life. “In the short years I’ve been practicing, the field has exploded with better options for patients, and I believe we’ve only just begun.”

Photo Credit: Annie O’Neill

Advertisement

Related Articles

Dr. Dedousis
November 2, 2026/Cancer/Podcast

Expanding Germline Genetic Testing in Oncology (Podcast)

Are we missing patients?

Dr. Hanlee Chung
October 29, 2026/Cancer/Podcast

Redefining Resectability in Advanced Rectal Cancer (Podcast)

Expanding treatment options for patients with advanced and recurrent rectal cancer

Patient and healthcare providers
October 28, 2026/Cancer/Patient Support

Desire for Preventative Screening is Strong Among People Experiencing Homelessness

Study analyzes creative approaches to support people facing housing insecurity

AI tech
October 26, 2026/Cancer/Innovations

AI Task Force Develops Unified Strategy to Integrate Tech Innovations

Evaluating AI initiatives and their impact on operations and care delivery

DNA test
October 23, 2026/Cancer/News & Insight

Early Genetic Testing Linked to Bilateral Mastectomy in Young BRCA Carriers with Breast Cancer

Study reinforces the importance of genetic testing prior to local therapy decisions

Dr. Arun Singh
October 21, 2026/Cancer

Preserving Vision in Uveal Melanoma (Podcast)

Understanding expanding treatment options and potential advances

Patient and doctor
October 9, 2026/Cancer/News & Insight

First Radioligand Therapy Approved for Metastatic Hormone-Sensitive Prostate Cancer

Adding 177Lu-PSMA-617 to ADT plus an ARPI cut the risk of radiographic progression or mortality by 28%

Woman running
October 7, 2026/Cancer/Patient Support

Pilot Project Aids Cancer Survivors in Achieving Healthy Weight and Reducing Recurrent Risk

New program will help patients improve fitness and manage weight after cancer treatment

Ad